0.11
—
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Argenica Therapeutics
Its shares trade on ASX under the ticker AGN.AX. It has been listed since 11 June 2021. In the fiscal year to 30 June 2025, it reported revenue of A$512,800 and a net loss of A$7.2m. At that date it held total assets of A$11.0m and shareholders' equity of A$7.2m.
Argenica Therapeutics Ltd. provides neuroprotective treatment. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2021-06-11. The firm is focused on developing therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. The firm's lead candidate, ARG-007, is a cationic arginine-rich peptide that aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury, in order to minimize the impact of these conditions and improve patient recovery. ARG-007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 11 Jun 2021
- Website
- argenica.com.au ↗
Leadership
Pay as last reported
- Ms. Dianne AngusNon-Executive Independent Chairman of the Board
- Dr. Liz DallimoreChief Executive Officer, Managing Director, Executive Director, since 2021A$336,789
- Ms. Emma WaldonCompany Secretary
- Dr. Mark EthertonNon-Executive Director
- Dr. Jeannie JoughinNon-Executive Director
- Mr. Terence BudgeNon-Executive Independent DirectorA$50,308
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Argenica Therapeutics Ltd. is focused on developing therapeutics for neuroprotective treatment after stroke and brain injury.
- The company's lead candidate, ARG-007, has shown positive results in pre-clinical models for stroke, TBI, and HIE.
- Argenica has completed an IPO on 2021-06-11, indicating market entry and potential for growth.
Weaknesses
- The company's lead candidate, ARG-007, has not yet been tested in human clinical trials.
- Argenica Therapeutics Ltd. is a relatively new company with an IPO in 2021, indicating limited operational history.
- The company's focus on neuroprotective treatments for brain injury and stroke may face significant regulatory hurdles.
Opportunities
- The growing global demand for treatments for stroke and neurodegenerative diseases presents a market opportunity.
- Successful clinical trials of ARG-007 could lead to significant market adoption and revenue growth.
- Collaborations with larger pharmaceutical companies could accelerate development and commercialization.
Threats
- Competition from other pharmaceutical companies developing similar neuroprotective treatments.
- Regulatory approval processes for new drugs can be lengthy and costly, delaying market entry.
- The high risk associated with drug development could lead to financial instability if trials fail.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.